The purpose of this scoping review is to describe and summarise the rationale behind and methodological approaches used to conduct cascade-of-care analyses for TB infection in low-TB incidence countries.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
Joint statement by the European Centre for Disease Prevention and Control, European Chemicals Agency, European Environment Agency, European Food Safety Authority and European Medicines Agency.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA.
This document provides an overview of public health guidance on testing for TB infection, TB preventive treatment and screening for TB disease, in the context of the mass influx of people arriving in European countries from Ukraine.
The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.